TEVA WITH A TWIST: LEMMON GENERICS' PARENT UP 1-5/8 IN OTHERWISE SOUR MARKET
Executive Summary
Teva Pharmaceutical Industries is gaining broader recognition with investors as a generics company with a twist: in addition to five ANDA approvals in 1993 for the company's Lemmon generics U.S. subsidiary, Teva is poised to announce results from a Phase III trial for its multiple sclerosis treatment, COP-1. Teva's new appeal moved the stock ahead 1-5/8 to 33-3/8 in February.